Phase III Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Sponsor: Akeso
Listed as NCT06396065, this PHASE3 trial focuses on Non-Squamous Non-small Cell Lung Cancer and remains ongoing. Sponsored by Akeso, it has been updated 8 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
- Summit Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .